Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibandronate + capecitabine
- Development stage
- Phase 3
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of ibandronate and capecitabine. Ibandronate is a bisphosphonate that inhibits bone resorption, while capecitabine is an oral fluoropyrimidine that is converted to 5-fluorouracil in tumor tissues. This combination was studied in the ICE trial for elderly patients with node-positive/high-risk node-negative early breast cancer. The trial found that the adjuvant combination of capecitabine plus ibandronate did not show significantly better invasive disease-free survival than ibandronate alone in these patients.
- Other names
- ibandronate and capecitabineICE regimen
02
Targets
FDPS (Farnesyl pyrophosphate synthase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on ibandronate + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibandronate + capecitabine.